|  |
| --- |
| **Supplementary Table S1. Associations of plasma 8-OHdG and F2-isoprostanes within subjects with current major depressive disorder and/or anxiety disorder(s) at baseline, presence of current diagnosis at two year follow-up, with remission during follow-up and chronicity of symptoms.** |
|  |  | **F2-isoprostanes** | **8-OHdG** |
|  |  |
|  |  | Model 1a basic adjustment | Model 2b+ antidepressant use | Model 1a basic adjustment | Model 2b+ antidepressant use |
|  |  |
|  |  |
|  |  | N | OR (95%CI) | p | OR (95%CI) | p | N | OR (95%CI) | p | OR (95%CI) | p |
|  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Current MDD and/or anxiety disorders  |  | 1196 | 1.23 (0.79-1.90) | .359 | 1.23 (0.80-1.90) | .353 | 1348 | 0.96 (0.71-1.29) | .794 | 1.01 (0.75-1.37) | .952 |
| (at 2 year follow-up; yes/no) |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Remission during 2 year follow-up (yes/no) |  | 992 | 1.24 (0.77-2.00) | .385 | 1.23 (0.76-2.00) | .393 | 1130 | 1.06 (0.77-1.46) | .731 | 0.99 (0.71-1.38) | .964 |
|  |  |  |  |  |  |  |  |  |  |  |  |
| Chronicity of symptoms (highest quartile; |  | 1196 | 0.80 (0.51-1.24) | .314 | 0.80 (0.51-1.25) | .323 | 1348 | 0.94 (0.70-1.27) | .698 | 1.01 (0.75-1.38) | .930 |
| symptomatic 75% of time in 2yr follow-up (yes/no) |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |

Logistic regression with current diagnosis at 2 year follow-up, remission yes/no during 2 year follow-up, or falling with in highest quartile of % of time with symptoms as dependent variables and baseline F2-isoprostanes or 8-OHdG as main predictors.

a Model 1 includes sampling variables: research site, season of sample collection, fasting prior to sample collection; socio-demographic variable: age, sex, education; health and lifestyle variables: plasma cotinine, alcohol, supplement use.

b Model 2 all factors in model 1 + antidepressant use yes/no.